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Abstract
Background: Granulosa cell tumors (GCTs) are relatively rare and are subtypes of the sex-cord
stromal neoplasms. Methylation induced silencing in the promoters of genes such as tumor
suppressor genes, DNA repair genes and pro-apoptotic genes is recognised as a critical factor in
cancer development.
Methods: We examined the role of promoter hypermethylation, an epigenetic alteration that is
associated with the silencing tumor suppressor genes in human cancer, by studying 5 gene
promoters in 25 GCTs cases by methylation specific PCR and RT-PCR. In addition, the compatible
tissues (normal tissues distant from lesion) from three non-astrocytoma patients were also
included as the control.
Results: Frequencies of methylation in GCTs were 7/25 (28 % for FHIT), 6/25 (24% for FNACF), 3/
25 (12% for Cyclin D2), 1/25 (4% for BRCA2) and 14/25 (56%) in RUNX3 genes. Correlation of
promoter methylation with clinical characteristics and other genetic changes revealed that overall
promoter methylation was higher in more advanced stage of the disease. Promoter methylation
was associated with gene silencing in GCT cell lines. Treatment with methylation or histone
deacetylation-inhibiting agents resulted in profound reactivation of gene expression.
Conclusions:  These results may have implications in better understanding the underlying
epigenetic mechanisms in GCT development, provide prognostic indicators, and identify important
gene targets for treatment.
Background
Ovarian cancer is one of the most common cancers in
women of all age groups. Among ovarian neoplasms,
granulosa cell tumors (GCTs) are relatively rare, account-
ing for approximately 3% of all ovarian cancers. One com-
mon DNA modification is promoter hypermethylation
associated with loss of expression of a tumor suppressor
gene. During cancer development, there is a shift in meth-
ylation patterns and some promoter region CpG islands
become methylated leading to silencing of the adjacent
genes [1] and this process is considered to be a critical step
in cancer development. The causes of methylation change
in normal cells remain unknown. It has been hypothe-
sised that fixation of methylation occurs when random
seeding of methylation occurs in the promoter regions of
silent genes [2]. Methylation seems to provide an ideal set
Published: 01 December 2004
Molecular Cancer 2004, 3:33 doi:10.1186/1476-4598-3-33
Received: 30 September 2004
Accepted: 01 December 2004
This article is available from: http://www.molecular-cancer.com/content/3/1/33
© 2004 Dhillon et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2004, 3:33 http://www.molecular-cancer.com/content/3/1/33
Page 2 of 8
(page number not for citation purposes)
of cancer specific markers for early detection of or for
monitoring response to treatment. However, the use of
methylation at a given site as a marker to detect low num-
bers of tumor cells relies on the background levels of
methylation in normal tissues to be nearly zero.
The human FHIT gene is a member of the histidine triad
gene family [3], the function of which remains unknown.
FHIT  gene has been shown to be hypermethylated in
oesophageal, lung, breast, prostate, bladder, cervical, and
oral cancers [4-9]. Recent studies indicate that FANC pro-
teins interact with both BRCA1 and BRCA2 genes through
a common pathway [10]. Methylation changes may dis-
rupt the FANC-BRCA pathway and hence may be a marker
change in the cancer development in granulosa cells of the
ovary. Aberrant expression of cyclin D2 was also demon-
strated in human ovarian granulosa cell tumors and testic-
ular germ cell tumor cell lines [11]. In breast cancer,
repression of expression was attributed to methylation of
the cyclin D2 gene promoter region. Several studies have
indicated that methylation of cyclin D2 and its mRNA and
protein were absent in most breast cancer cell lines exam-
ined and in primary breast cancers although normal
breast epithelial cells had abundant expression [12-14].
BRCA2 may play role in regulation of the cell cycle during
proliferation and differentiation. To date, only one study
has shown the absence of methylation in the promoter
region of BRCA2 in breast cancers cell lines and other nor-
mal human breast, bladder, colon, and liver tissues [15].
RUNX3 is one of the genes with RUNT domain, which has
been identified to have a tumor suppressor role that fre-
quently shows loss of expression due to hemizygous dele-
tion and hypermethylation in gastric cancers [16,17].
The role of epigenetic gene inactivation in GCTs of ovar-
ian origin is yet not fully understood. Previously pub-
lished reports on GCTs and its precursor lesions showed
varying degree of promoter methylation of many tumour
suppressor genes [18-20]. To investigate the role of pro-
moter methylation in detail in ovarian tumorigenesis, we
further evaluated CpG methylation of 5 more tumour
suppressor genes in 25 GCTs and cell lines. We found
68% of GCTs patients exhibiting promoter methylation in
at least one gene. The FHIT, FANCF and RUNX3 gene pro-
moters were frequently methylated. Methylation status
was correlated with histologic characteristics. We also
found evidence that promoter methylation inactivates
gene expression in GCTs and exposure to methylation
and/or histone deacetylase (HDAC)-inhibiting agents
reactivate the gene expression.
Results
We examined the hypermethylation status of a panel of 5
normally unmethylated tumor suppressor or cancer
genes: FHIT, FANCF, Cyclin-D2, BRCA2 and RUNX3 in 25
ovarian GCTs and ovarian cell line DNAs using the MSP
assay (Fig. 1). The frequency of promoter hypermethyla-
tion of the tumor suppressor gene loci included in the
panel was FHIT 28%,  FANCF 24%,  Cyclin-D2  12%,
BRCA2 4%, and RUNX3 56% of the 25 tumours (Table 1).
DNA methylation and mRNA expression results in 5 ovar-
ian cell lines are shown in Table 2. Fig. 2a and 2b shows
representative examples of MSP of each gene.
Hypermethylation was observed in all of the histological
stages of cancer examined and in patients of all ages
except BRCA2 which is seen in only one patient with stage
IC. Eighteen tumors showed methylation of at least 1
gene, and 7 tumors showed no methylation of any of the
5 genes. A total of 28% of these tumors had one gene,
16% two genes, 8% three genes and 8% four genes hyper-
methylated (Fig 1). No methylation was observed in 15
normal ovarian tissue DNAs and 50 lymphocyte DNAs
from females. Using statistical analysis, we examined
methylation with regard to these cancer patient clinico-
pathological parameters of age and stage. None of these
patients have any smoking history. FHIT methylation was
only found in all three stages of the tumors but was signif-
icantly more pronounced in IC (P = 0.041 vs IB). Hyper-
methylation of FANCF was significantly more frequent in
stage IC (P = 0.0312 when compared with IA and IB col-
lectively; P = 0.041 vs IB). Cyclin-D2  methylation was
Methylated profile of GCTs of ovarian origin in 25 patients  for FHIT, FANCF, cyclin-D2 and BRCa2 genes Figure 1
Methylated profile of GCTs of ovarian origin in 25 patients 
for FHIT, FANCF, cyclin-D2 and BRCa2 genes. Results were 
scored as methylated (dark boxes) or unmethylated (light 
grey boxes).Molecular Cancer 2004, 3:33 http://www.molecular-cancer.com/content/3/1/33
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found only in patients with IC type of cancer (P = 0.0017
vs. IA+ IB; P = 0.0088 vs. IA and P = 0.011 vs. IB; Table 1).
BRCA2 methylation was found only in one patient with
stage IC only cancer. RUNX3 methylation was found in all
the three stages of these tumours. However, all the
patients with stage IC showed methylation to associate
with high stage but not at a statistically significant level.
FANCF and Cyclin-D2 methylation was found to be more
pronounced in older than younger patients. However, we
are unable to amplify the modified DNA for either of the
PCR products.
Methylation is known to inactivate the tumour suppressor
genes. To test the hypothesis, we examined the expression
of all these genes except BRCA2 by RT-PCR after cellular
exposure to 5-Aza-2'-deoxycytidine (DAC). No FANCF
mRNA in TOV-21G, Cyclin-D2 in C13* and OV-90, and
RUNX3 in C13* and KGN was detected in untreated cell
lines (Table 2). However, DAC treatment for 120 hours
induced an increase in the detectable level of mRNA
expression in these cell lines and the tumors samples that
initially lacked the expression. We were unable to detect
expression of RUNX3 gene in patient 11 that also shows
no PCR products with either methylated or unmethylated
PCR primers. Further studies involving this patient with
markers specific for RUNX3 revealed the loss of heterozy-
gosity (LOH) which may be responsible for the loss of
expression (Data not given).
Discussion
Cancer cells especially of ovarian origin keep on accumu-
lating genetic changes that allow them to evade various
chemotherapeutic drugs and hence become increasingly
dangerous. We try to answer some of the questions by
exploring the role of methylation mediated gene silencing
in five tumour suppressor gene in the present study. We
asked a question whether hypermethylation of FHIT,
FANCF, cyclin-D2, BRCA2 and RUNX3 resulted in the loss
of gene expression. We performed reverse transcription-
PCR to test the expression of all these genes on RNA
extracted from tumour samples. With few exceptions,
expression of mRNA correlated well with promoter hyper-
methylation of these genes. This could be partly due to
complex process that controls gene expression in which
the chromatin conformation, cofactors availability,
repressor process and enhancer molecules all play a part.
Table 1: DNA methylation and mRNA expression in ovarian cancer cell lines
Cell line MSP mRNA expression
FHIT FANCF Cyclin-D2 BRCA2 RUNX3 FHIT FANCF Cyclin-D2 RUNX3
TOV-21G M M/U M U U + - + +
C13* M/U M M U M - + - -
OAW42 U M/U U U U + + + +
OAW28 U U U U U + + + +
OV-90 M/U U M U U + + - +
KGN M U U U M + + + -
Table 2: Association of grade classification (IA, IB and IC) and promoter methylation of different genes in granulosa cell tumours of 
ovarian origin
Genes Methylation Status Grade classification p-value* p-value† p-value** p-value‡ p-value#
IA IB IC
FHIT Methylated 3 1 3 1 0.0526 0.5856 0.2352 0.041#
Unmethylated 8 9 1
FANCF Methylated 2 1 3 0.6609 0.0312† 1 0.0769 0.041#
Unmethylated 9 9 1
Cyclin-D2 Methylated 0 0 3 0.23 0.0017† - 0.0088‡ 0.011#
Unmethylated 11 10 1
BRCA2 Methylated 0 0 1 1 0.16 - 0.2667 0.2857
Unmethylated 11 10 3
RUNX3 Methylated 7 3 4 0.6887 0.1052 0.1984 0.5165 0.0699
Unmethylated 4 7 0
*Fisher's exact test. IA type vs. IB and IC type; †Fisher's exact test. IA and IB type vs. IC type GCTs of ovarian origin;
**Fisher's exact test. IA type vs. IB; ‡Fisher's exact test. IA type vs. IC type; #Fisher's exact test. IB type vs. IC type GCTs of ovarian originMolecular Cancer 2004, 3:33 http://www.molecular-cancer.com/content/3/1/33
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The present study shows that methylation is one of the
important determinants, because in majority of the cases,
expression of these genes in these tumours correlates with
hypermethylation of the promoter sequences. We found a
link between aberrant methylation of genes investigated
and the clinicopathological features of stage IC, even
though the sample size was small. One has to bear in
mind that GCTs of ovarian origin constitute less than 5%
of the total ovarian cancers. Similar reports have been
reported for the FHIT methylation in highly malignant
osteosarcomatous [21]. Taken together, our results dem-
onstrate that promoter aberrant methylation of FHIT is an
important mechanism for inactivation of this tumor sup-
pressor gene in many malignancies. Cytogenetic investiga-
tion in these tumours revealed that chromosome 3 and 11
are found to carry deletions and reciprocal translocations
along with the trisomy 14 and monosomy 22. It could be
important because some of the tumour suppressor genes
(FHIT, RASSF1A, RAR-β and FANCF) studied extensively
in these tumours are in fact localised on these
chromosomes.
FANC genes are essential in DNA repair pathways and
recently, it has been shown that promoter hypermethyla-
tion of FANCF  gene disrupts the FA-BRCA pathway,
resulting in cisplastin resistance. We found FANCF pro-
moter hypermethylation in 24% of the tumours. This is in
line with the previous findings in squamous cell carcino-
mas of lung and oral cavity and, in cervical and ovarian
cancer [22-25]. To test whether other epigenetic mecha-
nisms such as partial methylation and histone deacetyla-
tion play a role, we examined the expression of all these
genes except BRCA2  after treatment with DAC. DNA
hypermethylation-mediated gene silencing is closely asso-
ciated with histone modifications such as methyl-H3-K9.
In this regard, DNA-demethylating agents 5'-aza-2'deoxy-
cytidine (DAC) and trichostatin (TSA) reactivates expres-
sion of epigenetically silenced genes [26]. Although DNA
hypermethylation is essential to maintain repressive state
of histone code, histone modifications precede DNA
hypermethylation in silencing specific genes [27,28]. In
the present study, reactivation and/or increased expres-
sion of FHIT, cyclin-D2 and RUNX3 in C13*, FANCF in
TOV-21G and cyclin-D2 in OV-90 cell line after exposure
to DAC in the absence of promoter methylation suggests
that key histone modifications, either by direct or indirect
involvement of promoter methylation, also play a role in
down-regulating FANCF gene expression in this cancer
type. It is therefore assumed that FANCF silencing might
be considered a candidate-mechanism underlying the
state of genomic instability may be considered to be a
rate-limiting in the origin of GCTs of ovarian origin.
FANCF gene silencing has been shown to revert in vitro as
a result of demethylation in some ovarian cell lines as
seen in the present study also [23]. These reversible
changes in the methylation status further complicate the
tumour assessment that shows the contribution of FANCF
methylation. The present finding along with the results
from other cancer types suggests the presence of genomic
instability due to the methylation mediated FANCF gene
silencing. Cyclin D2 gene promoter is hypermethylated in
12% of GCTs, a number that is consistent with previous
findings in other cancers [14,29,30]. We noted a trend
that  Cyclin D2 methylation is found only in IC type
tumors.
The present study showed that hypermethylation of the
RUNX3  gene promoter frequently occurred in ovarian
GCTs. In human gastric cancers it has been shown that
promoter hypermethylation and hemizygous deletion of
the RUNX3 gene correlated with a significant reduction in
expression, and the tumorigenicity of cell lines in nude
mice was inversely related to their level of RUNX3 expres-
sion, indicating that RUNX3  is a tumor suppressor
involved in the development of gastric cancers [17]. The
presence of RUNX3  CpG island hypermethylation in
GCTs, but not in normal ovarian tissue or peripheral
(a) Representative examples of MSP of FHIT, FANCF, Cyclin- D2 and BRCA2 genes in cell lines and tumor samples; -ve, neg- ative control (water blank PCR mixture without template);  +ve, positive control (normal lymphocyte DNA treated with  SssI methyl transferase) Figure 2
(a) Representative examples of MSP of FHIT, FANCF, Cyclin-
D2 and BRCA2 genes in cell lines and tumor samples; -ve, neg-
ative control (water blank PCR mixture without template); 
+ve, positive control (normal lymphocyte DNA treated with 
SssI methyl transferase). The unmethylated form of p16 was 
amplified as a control to check DNA integrity. (b) Repre-
sentative examples of MSP with RUNX3 gene and its expres-
sion before and after treatment with 5'-AZA-dC in different 
ovarian tissue (both normal and cancerous) using RT-PCR. 
UT: untreated; T: treated with 5'-AZA-dC; T2–T25: tumour 
samples.Molecular Cancer 2004, 3:33 http://www.molecular-cancer.com/content/3/1/33
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blood suggests that RUNX3 hypermethylation might be
associated with the genesis of this cancer type and this fre-
quent methylation might serve as a biological marker.
Loss of expression in RUNX3 gene in patient 11 which
also lacks any PCR product with either of the unmethyl-
ated and methylated primers indicates that it could be due
to the large deletion in the gene. However, studies involv-
ing the markers D1S234 and D1S199 showed the loss of
heterozygosity which could to some extent explain the
loss of expression in this patient. We could not confirm
this due to the lack of further sample. However, the sam-
ple quality was good as indicated by the presence of band
in GAPDH1 which was used as an internal control.
The histological examination of granulosa cells revealed
that these are small, usually round to polygonal, but may
be spindle-shaped with scanty amphophilic cytoplasm,
containing only occasional small lipid droplets, and hav-
ing indistinct cell borders. Granulosa cells regularly
express inhibin and contain vimentin and smooth muscle
actin intermediate filaments and, less commonly, cytok-
eratins. However, during their malignant transformation,
theses cells exhibit one or more of so-called 'microfollicu-
lar', 'macrofollicular', 'trabecular' or 'insular' patterns. The
microfollicular variant is characterized by multiple small
rounded spaces formed by cystic degeneration in small
aggregates of granulosa cells and often fragments of
nuclear debris or pyknotic nuclei. These spaces, known as
Call-Exner bodies, are found in only 30–50% of tumors.
The granulosa cell nuclei are oriented somewhat radially
around these structures. The nuclei are typically bland and
often grooved in granulosa cell tumors and have few
mitoses, but show variation in size and shape, and
marked hyperchromatism.
There exist two different pathways that can contribute to
the development of cancers; genome-wide hypomethyla-
tion may lead to the loss of chromosomes (as seen in
these tumours) leading to chromosomal instability,
whereas promoter methylation in tumour suppressor
genes, which are responsible for gene silencing, can lead
to the development of cancers in somatic cells. Therefore,
the balance in DNA methylation is very important, and
alteration in these may be protective in one pathway but
deleterious in the other.
Conclusions
In view of the high mortality rates associated with ovarian
cancer, a better understanding of the molecular mecha-
nisms underlying tumor progression in the disease could
reveal novel pathways of high clinical relevance. It can
therefore be concluded that promoter hypermethylation
of these genes, and loss of expression in ovarian cancers
(GCTs) is relatively common and this may also be useful
as a tumour marker for early diagnosis and subsequent
disease monitoring. Hence, these epigenetic signatures
could play a decisive role in designing treatment options
for this category of ovarian cancer. These results may also
have implications in better understanding the underlying
epigenetic mechanisms in GCT development thus can
provide prognostic indicators, and identify important
gene targets for treatment of this type of cancer in females.
Methods
Study Population
The subjects were 25 patients affected with GCTs of ovar-
ian origin without a positive family history. The study was
approved by the Health Research Ethics Board of the Fac-
ulty of Natural Sciences. All of them were untreated at the
time of study. Fifty normal individuals ranging in age
from 20–60 years were studied simultaneously under sim-
ilar experimental conditions. The tumor grading is as fol-
lows: 11 FIGO stage IA, 10 FIGO stage IB and 4 FIGO stage
IC. All these diagnoses were reviewed by a gynaecologic
pathologist and the tumor were assessed using standard
criteria. An informed consent was taken from all the sub-
jects prior the study. Fresh cancer tissue specimens were
received from all the patient and these were cultured as
per standard protocol. A part of the fresh tissue was used
to isolate DNA and RNA for further analysis where as the
cultured cells were used for the 5'-Aza-2'-deoxycytidine
experiments. Microscopically, GCTs are composed of
granulosa cells, theca cells, and fibroblasts in varying
amounts and combinations. The term granulosa-theca
cell tumor had been applied to all tumors in which both
cell types were identified, regardless of the amounts
present.
Cell Lines and DNA Isolation
Five human ovarian cancer cell lines (TOV21G, C13*,
OAW28, OAW42, OV90 and KGN) from the American
Type Culture Collection and European Collection of Cell
Culture were maintained in RPMI 1640 supplemented
with 10% fetal bovine serum (Hyclone, Logan, UT) and
were grown at 37°C in 5% CO2 [31]. DNA was isolated
from cultured cells using QIAamp DNA Mini kit (Qiagen
Inc.) and quantified. LOH studies were performed using
markers D1S199 and D1S234 specific for locus 1p36.11.
Methylation Status by Methylation-Specific PCR (MS-
PCR)
DNA methylation patterns in CpG islands of tumor sup-
pressor genes FHIT, FNACF and BRCA2 were determined
by chemical modification with sodium bisulphite as
described previously [32]. Briefly, 1 µg DNA l was dena-
tured by NaOH (50 µl, final concentration, 0.2 M) for 10
min at 37°C. 1 µg of salmon sperm DNA (Sigma) was
added as carrier before modification. Freshly prepared 30
µl of hydroquinone (10 mM, Sigma) and 520 µl of
sodium bisulfite (3 M, pH 5.0, Sigma) were mixed andMolecular Cancer 2004, 3:33 http://www.molecular-cancer.com/content/3/1/33
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samples were incubated under mineral oil at 55°C for 16
hr. The DNA samples were desalted through Wizard col-
umns (Promega, Madison, WI), desulfonated by NaOH
(final concentration, 0.3 M) for 5 min at room tempera-
ture, followed by ethanol precipitation. DNA was resus-
pended in water and used immediately or stored at -20°C.
50 µl of bisulphite modified DNA was used for each MSP.
Following primer pairs for FHIT gene, methylated CpG
site, forward 5'-ttggggcgcgggtttgggtttttacgc-3' and reverse
5'-cgtaaacgacgccgaccccacta-3', unmethylated CpG site, for-
ward 5'-ttggggtgtgggtttgggtttttatg-3', and reverse 5'-cat-
aaacaacaccaaccccacta-3'; 189–262 bp relative to
transcription start site, FANCF gene, methylated CpG site,
forward 5'-tttttgcgtttgttggagaatcgggttttc-3' and reverse 5'-
atacaccgcaaaccgccgacgaacaaaacg-3', unmethylated CpG
site, forward 5'-tttttgtgtttgttggagaattgggttttt-3' and reverse
5'-atacaccacaaaccaccaacaaacaaaaca-3'; the primers corre-
sponds to the position +280 to +432, BRCA2 gene, meth-
ylated CpG site, forward 5'-gacggttgggatgtttgataagg-3' and
reverse 5'-aatctatcccctcacgcttctcc-3', unmethylated CpG
site, forward 5'-agggtggtttgggatttttaagg-3' and reverse 5'-
tcacacttctcccaacaacaacc-3'; these primers are 135 and 211
bp upstream of transcription start site and cyclin-D2 gene,
methylated, forward 5'-tacgtgttagggtcgatcg-3' (-1427 to -
1409) and reverse 5'-cgaaatatctacgctaaacg-3' (-1152 to -
1171) and unmethylated, forward 5'-gttatgttatgtttgttgtatg-
3' (-1616 to -1594) and reverse 5'-taaaatccaccaacacaatca-3'
(-1394 to -1414). Each PCR reaction generated 74 bp
products both with methylated and unmethylated prim-
ers for FHIT, 153 bp for FANCF both with methylated and
unmethylated primers, 337 and 250 bp product with
BRCA2 primers specific for methylated and unmethylated
primers and 276 and 222 bp product for cyclin-D2 primers
specific for methylated and unmethylated PCR reactions
respectively. For the PCR reaction of 25 µl, 50 ng sodium
bisulfite treated DNA was added to reaction buffer con-
taining 0.2 mM dNTP, 16.6 mM (NH4)2SO4, 67 mM Tris
pH 8.8, 10 mM β-mercaptoethanol, 1.5 mM MgCl2, 10
pmol of forward and reverse primers specific to the meth-
ylated and methylated DNA sequences and 1.25 units of
AmpliTaq Gold (PE Biosystems, Foster City, CA, USA).
The PCR reactions were cycled in a GeneAmp 9600 ther-
mal cycler (Applied Biosystems) under the following con-
ditions: preheat at 94°C for 3 min. followed by 40 cycles
(94°C for 40 sec, 65°C for 40 sec, for FHIT, 4 cycles of
65°C and 36 cycles of 55°C for 60 seconds for FANCF and
62°C or 56°C for 40 seconds in methylated or unmethyl-
ated BRCA2 gene, 72°C for 45 sec and a final extension at
72°C for 7 min. The PCR conditions for cyclin-D2 are as
follows: 1 cycle of 95°C for 5 min and 35 cycles at 95°C
for 30 s, 55°C for 30 s, and 72°C for 45 s; and 1 cycle of
72°C for 5 min. In addition to these genes we also inves-
tigated the RUNX3 gene (Accession no AL023096) meth-
ylation status using the primers: forward, 5'-
ataatagcggtcgttagggcgtcg-3', and reverse, 5'-gcttctactttc-
ccgcttctcgcg-3' (64917–65031; 115 bp), for methylated
DNA of RUNX3; and forward, 5'-ataatagtggttgttagggtgttg-
3', and reverse, 5'-acttctactttcccacttctcaca-3' (64917–
65031; 115 bp), for unmethylated DNA of RUNX3 with
annealing temperature of 55°C for 20 seconds. For each
PCR set, DNA isolated from normal peripheral lym-
phocytes of healthy individuals served as a negative meth-
ylation control. Human placental DNA was treated in
vitro with SssI methyltransferase (NEB, Beverly, USA) to
create completely methylated DNA at all CpG-rich regions
and served as positive methylation control. Methylation-
specific PCR products were analysed on 3% agarose gel
electrophoresis with ethidium bromide staining. A posi-
tive control and a negative control were included in each
amplification reaction.
FHIT, FANCF, Cyclin-D2 and RUNX3 Expression by RT-
PCR
FHIT,  FNACF  and  cyclin-D2  mRNA levels in cancer
patients were compared to their expression in normal cells
using semi-quantitative reverse transcriptase polymerase
chain reaction. In brief, cDNA was synthesized using AMV
reverse transcriptase (Promega, Mannheim, Germany)
and amplified in duplex reactions in a total volume of 25
µl containing 150 µM of each dNTP, 1.5 mM MgCl2, 10
pmol of each primer pair and 1.0 units of Taq polymerase.
After initial denaturation at 95°C (94°C) for 5 min, 30
cycles of 30 sec (45 sec) at 95°C (94°C), 30 sec (50 sec)
at 58°C (55°C) and 45 sec (50 sec) at 72°C were
performed followed by a final 10 min elongation step at
72°C. The values in the brackets correspond to FANCF.
The following primers were used to amplify FHIT: forward
5'-gctcttgtgaataggaaacc-3' and reverse 5'-tcactggttgaagaata-
cagg-3' which yields 532 bp product spanning within
exon 5 to exon 10, FANCF: forward 5'-ttcggaagtctttgctgcct-
3' and reverse 5'-agtaataacacacgattgcc-3' which yields 413
bp product spanning from +733 to +1144. RT-PCR was
performed for Cyclin D2 using the primers 5'-catggagctgct-
gtgccacg-3' (forward) and 5'-ccgacctacctccagcatcc-3'
(reverse) with PCR conditions being: 1 cycle of 94°C for
3 min and 35 cycles at 94°C for 20 s, 55°C for 30 s, 72°C
for 45 s followed by 72°C for 5 min. RT-PCR was also car-
ried out for RUNX3 gene using the primers: forward 5'-
aggcattgcgcagctcagcggagta-3' and reverse 5'-tctgctccgtgct-
gccctcgcactg-3' (152 bp). GAPDH1 was used as internal
control. Each reaction was performed in triplicate. PCR
products were electrophoresed on 2% agarose gels and
quantified using densitometer (Molecular Dynamics).
Fold increases in expression in cancer cells were calculated
with respect to the levels of the transcripts in normal cells.
5-Aza-2'-deoxycytidine and n-butyrate treatment
Cell lines (TOV21G, C13*, OAW28, OAW42 and OV90),
normal ovarian cells and tumour cells of ovarian GCTs
were treated with demethylating agent 5-Aza-2'Molecular Cancer 2004, 3:33 http://www.molecular-cancer.com/content/3/1/33
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deoxycytidine (Sigma) for five days at a concentration of
2.5 µM, HDAC-inhibiting agent trichostatin (TSA) at a
final concentration of 5 µM for the last 24 hours or a com-
bination of both. Total RNA isolated from treated,
untreated cell lines and cell of the cancerous tissue was
reverse transcribed using random primers and the Pro-
STAR first strand RT-PCR kit (Stratagene, La Jolla, CA). A
semi-quantitative analysis of gene expression was per-
formed in replicate experiments using 30 cycles of RT-PCR
as described above.
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